Open AccessThe clinical impacts of molecular subtyping by multigene assay on hormone receptor-positive breast cancers
Author(s) -
Yeng-Ling Liu,
ChihYi Hsu,
Chin-Jung Feng,
PeiJu Lien,
ChiCheng Huang,
YuanYung Lin,
Yuling Wang,
TaChung Chao,
Chunyu Liu,
JenHwey Chiu,
YiFang Tsai,
LingMing Tseng
Publication year - 2022
Publication title -
journal of the chinese medical association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.535
H-Index - 42
eISSN - 1728-7731
pISSN - 1726-4901
DOI - 10.1097/jcma.0000000000000657
Subject(s) - subtyping , medicine , oncology , immunohistochemistry , breast cancer , progesterone receptor , hormone receptor , estrogen receptor , cancer , computer science , programming language
Multigene assays, such as MammaPrint and BluePrint, provide additional information other than conventional immunohistochemistry (IHC) to help making decision of treatment. This study aims to compare the clinical correlation between molecular subtyping (MS) versus surrogate pathological subtyping (PS).